Citation

BibTex format

@article{Ndow:2024:10.1016/S2468-1253(24)00226-7,
author = {Ndow, G and Shimakawa, Y and Leith, D and Bah, S and Bangura, R and Mahmoud, I and Bojang, L and Ceesay, A and Drammeh, S and Bola-Lawal, Q and Lambert, G and Hardy, P and Ingiliz, P and Haddadin, Y and Vo-Quang, E and Chevaliez, S and Cloherty, G and Bittaye, SO and Lo, G and Toure-Kane, C and Mendy, M and Njie, R and Chemin, I and D'Alessandro, U and Thursz, M and Lemoine, M},
doi = {10.1016/S2468-1253(24)00226-7},
journal = {Lancet Gastroenterol Hepatol},
pages = {1133--1146},
title = {Clinical outcomes of untreated adults living with chronic hepatitis B in The Gambia: an analysis of data from the prospective PROLIFICA cohort study.},
url = {http://dx.doi.org/10.1016/S2468-1253(24)00226-7},
volume = {9},
year = {2024}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Expanding antiviral therapy to people with chronic hepatitis B virus (HBV) infection who are ineligible to receive treatment under current international criteria has been increasingly debated. Evidence to support this approach is scarce, especially in Africa. We aimed to address this knowledge gap by analysing the clinical outcomes of people with chronic hepatitis B in The Gambia who were untreated and ineligible for antiviral therapy at diagnosis. METHODS: Between Dec 7, 2011, and Jan 24, 2014, we implemented the prospective PROLIFICA cohort study in The Gambia. Participants with chronic hepatitis B aged 16 years or older were recruited after large-scale, community-based HBV screening; blood bank-based HBV screening in Edward Francis Small Teaching Hospital, Banjul; and prospective follow-up of HBsAg-positive individuals via historical, population-based HBsAg serosurveys in two rural villages (Keneba and Manduar). Participants underwent HBV serology and other laboratory tests, fasting FibroScan, and abdominal ultrasound. Survival data were collected between Dec 7, 2011, and Aug 17, 2021. Between Oct 9, 2018, and Aug 17, 2021, all HBsAg-positive participants enrolled in the 2011-14 cohort were invited for a reassessment. For this analysis, we included HBsAg-positive people and excluded all participants who were eligible for treatment according to the 2012 European Association for the Study of the Liver (EASL) criteria at baseline and those who were treated irrespective of treatment eligibility. The primary outcome was all-cause mortality, assessed in all treatment-ineligible and treatment-naive participants with follow-up data. The secondary outcome, analysed in those who were reassessed, was disease progression, defined as becoming eligible for antivirals per 2017 EASL criteria; having an increase in liver fibrosis of at least one stage; or having a clinical diagnosis of hepatic decompensation or hepatocellular carcinoma. FINDINGS: 943 HBsAg-positive pe
AU  - Ndow,G
AU  - Shimakawa,Y
AU  - Leith,D
AU  - Bah,S
AU  - Bangura,R
AU  - Mahmoud,I
AU  - Bojang,L
AU  - Ceesay,A
AU  - Drammeh,S
AU  - Bola-Lawal,Q
AU  - Lambert,G
AU  - Hardy,P
AU  - Ingiliz,P
AU  - Haddadin,Y
AU  - Vo-Quang,E
AU  - Chevaliez,S
AU  - Cloherty,G
AU  - Bittaye,SO
AU  - Lo,G
AU  - Toure-Kane,C
AU  - Mendy,M
AU  - Njie,R
AU  - Chemin,I
AU  - D'Alessandro,U
AU  - Thursz,M
AU  - Lemoine,M
DO  - 10.1016/S2468-1253(24)00226-7
EP  - 1146
PY  - 2024///
SP  - 1133
TI  - Clinical outcomes of untreated adults living with chronic hepatitis B in The Gambia: an analysis of data from the prospective PROLIFICA cohort study.
T2  - Lancet Gastroenterol Hepatol
UR  - http://dx.doi.org/10.1016/S2468-1253(24)00226-7
UR  - https://www.ncbi.nlm.nih.gov/pubmed/39521002
VL  - 9
ER  -
Download